Aeterna Zentaris Inc. (0UGB.L)
Chart Events
Performance Outlook
| Previous Close | 0.00 |
| Open | N/A |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | N/A - N/A |
| 52 Week Range | undefined - undefined |
| Volume | |
| Avg. Volume | N/A |
| Market Cap | N/A |
| Beta (5Y Monthly) | 1.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Nov 01, 2023 - Nov 06, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for 0UGB.L
Related Research
GlobeNewswireAeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment Conference
TORONTO, ONTARIO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY in person and virtually. Dr. P
ZacksAeterna Zentaris (AEZS) Reports Q2 Loss, Tops Revenue Estimates
Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of 40.23% and 104.18%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Aeterna Zentaris Reports Second Quarter 2023 Financial Results
Ended the quarter with $42.2 million in cash, expected to fund operations into 2025Driving patient recruitment for Phase 3 DETECT trial for the diagnosis of Childhood Onset Growth Hormone Deficiency TORONTO, ONTARIO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and o
